We are live on ! Find out more
ESLAW icon

Estrella Immunopharma Warrant
ESLAW

16 hedge funds and large institutions have $2.64M invested in Estrella Immunopharma Warrant in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

23% more funds holding

Funds holding: 13 → 16 (+3)

2% more capital invested

Capital invested by funds: $2.59M → $2.64M (+$49.6K)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
4
Closed
1
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
YCM
Yakira Capital Management
Connecticut
+$5.58K
2
SIA
SkyView Investment Advisors
New Jersey
+$5.22K
3
LCM
Landscape Capital Management
New Jersey
+$1.14K
4
CS
Clear Street
New York
+$823
5
Bank of America
Bank of America
North Carolina
+$25

Top Sellers

Rank Fund Capital Flow
1
EFI
EHP Funds Inc
Canada
-$1.93K
2
KPF
K2 Principal Fund
Ontario, Canada
-$819
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$466
4
CH
CVI Holdings
Delaware
-$54
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$2.08M – – –
RCM
2
Radcliffe Capital Management
Pennsylvania
$515K – – –
ASM
3
ATW SPAC Management
New York
$10.1K – – –
EFI
4
EHP Funds Inc
Canada
$9K -$1.93K -23,095 -12%
KPF
5
K2 Principal Fund
Ontario, Canada
$6.98K -$819 -9,792 -7%
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$4.55K – – –
CH
7
CVI Holdings
Delaware
$4.48K -$54 -640 -0.7%
YCM
8
Yakira Capital Management
Connecticut
$3.47K +$5.58K +66,785 New
SIA
9
SkyView Investment Advisors
New Jersey
$3K +$5.22K +62,500 New
Hudson Bay Capital Management
10
Hudson Bay Capital Management
Connecticut
$2.7K – – –
WA
11
Whitebox Advisors
Minnesota
$2.37K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$1.17K -$466 -5,580 -20%
SSA
13
Schonfeld Strategic Advisors
New York
$1.01K – – –
CS
14
Clear Street
New York
$1K +$823 +9,841 +55%
LCM
15
Landscape Capital Management
New Jersey
$711 +$1.14K +13,682 New
Bank of America
16
Bank of America
North Carolina
$16 +$25 +300 New

ESLAW Hedge Fund Activity: Q4 2022 in Review

16 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q4 2022, worth a combined $2.64M — up 1.9% from $2.59M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ESLAW positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Yakira Capital Management, opening a new position worth an estimated $5.58K. The largest seller was EHP Funds Inc, cutting an estimated $1.93K.

  • 16 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q4 2022, up from 13 in Q3 2022.
  • Funds reported $2.64M of Estrella Immunopharma Warrant stock for Q4 2022, up 1.9% quarter-over-quarter.
  • 4 funds opened new Estrella Immunopharma Warrant positions in Q4 2022 and 1 closed out, a net change of +3 holders.
  • The largest Estrella Immunopharma Warrant buyer in Q4 2022 was Yakira Capital Management, an estimated $5.58K added.
  • The largest Estrella Immunopharma Warrant seller in Q4 2022 was EHP Funds Inc, an estimated $1.93K sold.

Based on aggregated 13F filings for Q4 2022.